Product correctly added to cart.

discount label
RD 162
View 3D

Biosynth logo

RD 162

CAS: 915087-27-3

Ref. 3D-FR103318

1mgTo inquire
5mgTo inquire
10mgTo inquire
Estimated delivery in United States, on Thursday 9 Jan 2025

Product Information

Name:
RD 162
Description:

RD 162 is a potent, selective small molecule inhibitor of NF-kB. It is currently being investigated as a potential treatment for prostate cancer and other diseases in which NF-kB plays an important role. RD 162 selectively inhibits the activation of NF-kB by targeting the IKK complex. This agent disrupts the interaction between IKKα and IκB, thereby inhibiting the phosphorylation of IκB and preventing it from entering the nucleus. RD 162 also has been shown to reduce tumor size in mouse models with prostate cancer cells that are resistant to hormone therapy and chemotherapy. RD 162 has been shown to be chemically stable, even at high concentrations and in plant cells.

The product name is 6-Fluoro-3-indoxyl beta-D-galactopyranoside
Rifapentine is an anti-tuberculosis drug that belongs to the class of rifamycins. It is the most active of the rifamy

Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Molecular weight:
476.45 g/mol
Formula:
C22H16F4N4O2S
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-FR103318 RD 162

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".